CD8A and metabolic dysfunction-associated steatohepatitis: CD4+CD28−CD57+ and CD8+CD28−CD57+ T cells increased 2.9- and 1.3-fold, respectively (both p < 0.05), in T2DM individuals with NASH or cirrhosis vs. those without liver disease [22].